Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal
Status:
Recruiting
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This is a dose-ranging study to support the safety and efficacy evaluation of BXCL501 to
treat the symptoms of acute opioid withdrawal. The BXCL501-201 study is designed to
characterize the efficacy, safety, tolerability, and pharmacokinetics of escalating doses of
BXCL501 (sublingual film formulation of DEX, HCl) versus placebo following discontinuation of
morphine maintenance in patients with opioid use disorder who are physically dependent on
opioids.